Lumos Pharma, Inc. Common Stock
LUMO US55028X1090 inactive
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -78% | -51% | -18% | 34% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Mckew John C. CSO |
1.89 USD |
3,407 Sold |
6,426 USD |
06/08/2024 | 06/08/2024 |
| Mckew John C. CSO |
2.78 USD |
2,214 Sold |
6,144 USD |
01/04/2024 | 03/04/2024 |
| Mckew John C. CSO |
3.03 USD |
438 Sold |
1,328 USD |
06/02/2024 | 06/02/2024 |